

Serina Therapeutics to Co-Sponsor Session on Poly(2-oxazoline)s and Polypeptoids at American Chemical Society in San Francisco August 10-12th 2014

Huntsville, AL, August 8th 2014

Serina Therapeutics, Inc., a pharmaceutical development company that is advancing a proprietary, patented polymer technology for drug development, announced today that the company is co-sponsoring the session on “Poly(2-oxazoline)s and Polypeptoids” at the American Chemical Society meeting to be held in San Francisco from August 10-12th, 2014.

“I am delighted to be invited to represent Serina Therapeutics, Inc. at the ACS Meeting in San Francisco. This is an exciting and important new area of drug development in the field of polymer drug conjugates, with great interest from both the academic communities as well as pharmaceutical companies,” said Randall Moreadith, MD, PhD, President and Chief Executive Officer at Serina Therapeutics. Dr. Moreadith will give an invited talk on August 12th entitled “POZ - A Next Generation Polymer for Drug Development.”

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that develops polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms. Serina Therapeutics’ most advanced compound is SER-214, a novel polymer-conjugate that is being developed for treatment of Parkinson’s disease and restless leg syndrome. The pipeline programs are focused largely on development of targeted therapies for oncology indications. The founders and executives of Serina were formerly the key principals of Shearwater Polymers, a company that enabled twelve approved polyethylene glycol (PEG) products for various pharmaceutical partners - with nine therapeutics marketed in 2013 for revenue in excess of \$ 7 billion USD. Besides developing its own pipeline of pharmaceutical products for Parkinson’s disease and cancer, Serina has partnered its technology with pharmaceutical companies such as AstraZeneca to develop POZ-therapeutics addressing unmet medical needs.

For more information on Serina Therapeutics, please visit <http://www.serinatherapeutics.com>